key: cord-0863879-ajeob4ae
authors: Silveira, Marcelle Moura; Moreira, Gustavo Marçal Schmidt Garcia; Mendonça, Marcelo
title: DNA vaccines against COVID-19: Perspectives and challenges
date: 2020-12-19
journal: Life Sci
DOI: 10.1016/j.lfs.2020.118919
sha: 496c6f337ef45011e4b205b9df818387b5554a0e
doc_id: 863879
cord_uid: ajeob4ae

The coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is associated with several fatal cases worldwide. The rapid spread of this pathogen and the increasing number of cases highlight the urgent development of vaccines. Among the technologies available for vaccine development, DNA vaccination is a promising alternative to conventional vaccines. Since its discovery in the 1990s, it has been of great interest because of its ability to elicit both humoral and cellular immune responses while showing relevant advantages regarding producibility, stability, and storage. This review aimed to summarize the current knowledge and advancements on DNA vaccines against COVID-19, particularly those in clinical trials.

In the second week of December 2019, patients with an atypical form of pneumonia were diagnosed in Wuhan, Hubei Province, China [1] . At this time, it was detected as a new coronavirus, initially named nCoV-2019. In mid-January, the genome of this pathogen was made public, with its precise definition as "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2), thus named "coronavirus disease 2019" . This virus has spread rapidly across mainland China and worldwide. On March 11, the World Health Organization declared a pandemic state to the whole world [2] [3] [4] [5] .

Coronaviruses are a large family of viruses known to cause illnesses in different animals, ranging from the common cold to more severe diseases. As of this year, seven different coronaviruses from alpha and beta genera are known to infect and cause disease in humans. These include the betacoronaviruses that cause severe acute respiratory syndrome (SARS-CoV), the Middle East respiratory syndrome (MERS-CoV) [3] , and SARS-CoV-2, all of which were responsible for a relatively high number of cases with high mortality rates. As of mid-August 2020, COVID-19 has already been responsible for more than 20 million infections and 750 thousand deaths [2] . As transmission rates are shown to be higher than other coronaviruses, SARS-CoV-2 is [6] . However, no coronavirus vaccine to prevent respiratory infections in humans has been licensed yet [7] .

In this context, various groups have made remarkable advances in developing new vaccines in a very short time [8] . Traditional vaccine development methods, although extremely effective in combating highly contagious diseases such as measles, require a large number of active viruses during production and can even take a longer time for the development in case attenuated pathogens are needed. Thus, more advanced vaccine technologies, such as DNA, RNA, subunit, and virus-like particles, have been extensively tested [9] . The aim of this study was to elucidate the current knowledge and discuss the use of DNA vaccines against COVID-19.

For human vaccine development, regulatory agencies of different countries have historically requested an increasing number of clinical studies with a large number of patients and complexity. These measures assure that the final vaccine product will be safe and effective for different population subgroups before licensure for commercial use. Typically, 10-15 years are required from conducting preclinical studies to obtaining vaccine licensure. The fastest approval, though, was the Ebola vaccine, which took five years [10] .

In brief, clinical tests in humans can be divided into four phases: phase 1, wherein the vaccine is given to the healthy volunteers, and its safety and dosing are determined; phase 2, wherein initial immune stimulation is evaluated, and safety is further explored in small numbers of healthy people; phase 3 wherein the vaccine efficacy in preventing the disease is determined after it is given to a large cohort; and phase 4 which is conducted after vaccine approval to guarantee its safety and study long-term effects J o u r n a l P r e -p r o o f Journal Pre-proof [11] . The necessity of these phases is unanimous in the vaccinology field. However, the time required for each of these steps needs to be better planned to fasten the process and obtain the approval of a vaccine during a pandemic situation.

The vast majority of viral vaccines currently licensed for humans can be categorized as virus or protein based. The virus-based group consists of an inactivated or liveattenuated virus, and even though these vaccines are more immunogenic, several limitations are associated with these approaches. In the case of SARS-CoV-2, large quantities of viruses need to be produced under biosafety level 3 conditions for an inactivated vaccine, and extensive safety testing is required to ensure they do not revert to infective [12] . In contrast, subunit vaccines such as those with purified proteins present higher safety and scalability than whole-pathogen vaccines. Nevertheless, they may show less immunogenicity and require multiple immunizations [13, 14] .

The current life-threatening infectious diseases, such as influenza (H5N1 subtype), Zika, Ebola, and MERS-CoV, are driving the demand for new, faster, and effective vaccine platforms [15, 16] . Considering recent experiences from the SARS-CoV-2 pandemic, next-generation platforms must allow having a vaccine formulation useful for clinical trials in less than 16 weeks from genome sequencing to application in humans. Furthermore, these technologies elicit consistent immune responses across different pathogens and are suitable for large-scale manufacturing even as a pathogenagnostic platform. Multiple approaches are still under development; however, the DNAand RNA-based approaches are among those with the greatest potential for speeding up about its clinical trials to prove its safety and efficacy [11] . Although there is a consensus that developing a safe and effective vaccine against SARS-CoV-2 is crucial to end the COVID-19 pandemic, cautious measures are necessary to ensure that new vaccines are safe for the entire population [18] . In addition, efficacy and safety are not the only crucial criteria, as a vaccine candidate must also have scalable production.

Thus, it is necessary to select an adequate vaccine platform for accelerating vaccine development.

Immunization with nucleic acids has received considerable attention in the field of new generation vaccines. The first proof of concept of a DNA vaccine was made in 1990 and involved the injection of RNA or DNA molecules, expressing chloramphenicol acetyltransferase, luciferase, and beta-galactosidase into mouse skeletal muscle, and the expression of reporter genes in vivo, which can be detected for up to two months after infection [19, 20] . In brief, DNA vaccine consists of delivering genes or fragments of it, encoding immunogenic antigens to the host's cells by using DNA plasmids as a vector.

This approach induces both humoral and cell-mediated immune responses efficiently [21, 22] . The vaccine formulation is made such that the genetic material is translocated to the host's cell nucleus (Fig. 1 ). Once it reaches there, the mammalian promoter present in the vector structure is activated, triggering the transcription of the gene used for the vaccine through the host's cellular machinery. The antigen-presenting cells (APCs) are the major target cells to receive the genetic material. In addition, myocytes (DCs), can use MHC-II, resulting in cross-priming and presentation of antigens to both CD4+ and CD8+ T cells [23] [24] [25] [26] . Regarding COVID-19 immune regulation, a recent study showed that at-risk patients with pericardial effusion with a worse prognosis show elevated CD3 + CD8 + T cells together with reduced Tregs and CD14 + HLA-DR + monocytes [26] . These findings show that the main course of the disease occurs because of a misbalance of the immune response, often leading to misregulation and worsening of the infection [27] . Thus, the vaccines in development against COVID-19 aim to build a proper and effective immune response without causing such misbalance. Of note, not only this cellular immune response can be activated, but also humoral responses can be triggered if the produced immunogen is released from the cells and recognized by B cell

In addition, intrinsic elements of plasmid DNA, such as CpG unmethylated sequences, can activate innate immune responses, thereby enhancing adaptive immune responses against the expressed antigens. Although clinical trials using DNA vaccines in humans induced both cellular and humoral responses, these responses are often not sufficient to elicit significant clinical benefits. Therefore, DNA vaccines have only been licensed for use in veterinary medicine [21, 24, 25] . Because of this limitation, several research lines focus on DNA vaccine optimization and delivery, including promoter design, codon optimization, adjuvants, use of electroporation, prime/boost immunization, or "omics" approaches for refined vaccine design [28] .

through the action of proteases. Currently, the main receptor for SARS-CoV-2 entry in humans is angiotensin-converting enzyme 2 (ACE2), which is also used by SARS-CoV [32] [33] [34] [35] .

Structurally, SARS-CoV-2 contains four structural proteins, including spike (S), envelope (E), membrane (M), and nucleocapsid (N). Moreover, these proteins share high sequence similarity to those from SARS-CoV and MERS-CoV [32] . Thus, the knowledge from SARS-CoV and MERS-CoV vaccines provides some insights and lessons concerning the development of SARS-CoV-2 vaccine design and thus helps in accelerating the development of new vaccines for COVID-19 [18] . Some successful DNA vaccines expressing S, M, and N proteins have been developed against SARS-CoV. The obtained results confirmed the strong protective humoral and cellular immune responses in mice, macaques, and camels [36] [37] [38] [39] [40] . Furthermore, the first DNA vaccine candidate against MERS-CoV to enter clinical trials, named GLS-5300, was well tolerated with no vaccine-associated serious adverse events. Immune responses were dose-independent, detected in more than 85% of participants after two immunization regimens, and durable through one year of follow-up [41, 42].

The immune system can be categorized into innate immunity (rapid and nonspecific response) and adaptive immunity (slow and specific response). The adaptive immunity can be further divided into cellular responses mainly characterized by T cell maturation and humoral responses characterized by B cell maturation. Considering this, vaccines are prepared to induce both arms of the adaptive immune system and stimulate a sufficient number of memory T and B cells. Furthermore, immunity can be divided into two types: active and passive. Active immunity refers to the process of exposing a J o u r n a l P r e -p r o o f Journal Pre-proof patient to an antigen to generate an adaptive immune response, and passive immunity refers to the transfer of antibodies from one individual to another [43] .

Moreover, passive immunity can occur naturally when maternal antibodies are transferred to the fetus through the placenta or from breast milk to the gut of the infant [43, 44] . Regarding immunity against COVID-19, it is still not completely clear, which responses occur in natural COVID-19, and if people who recover from COVID-19 infection are protected from a second infection [45, 46] .

cells. In addition, both immunoglobulin (Ig)M and IgG antibodies are produced mainly against N and S proteins. The antibodies appear around the 10 th day of infection, and most patients seroconvert within three weeks. If reinfections occur, it would indicate that immune response against SARS-CoV-2 is not protective and, therefore, the use of vaccines could not be associated with protection [47] .

On the other hand, SARS-CoV-2 antibodies are found to be protective, although it remains uncertain if a high level of circulating antibodies lasts for enough duration to avoid further infections. This question still cannot be properly answered, as SARS-CoV-2 has been in the community only for the past few months. However, results obtained with other closely related coronaviruses, mainly SARS-CoV and MERS-CoV, showed robust, long-lasting T and B cell immune responses [48] [49] [50] .

As of January 2020, the complete genome of SARS-CoV-2 was published.

Understanding the genome structure of the virus is a critical step for the development of initiating the infection to the host cell [52] . The S protein has 1273 amino acid residues and can be divided into three subunits, S1, S2, and S2', each having a different role during the adherence to the host cell [52] .

The S1 subunit is involved in the attachment of virions to the host cell membrane by interacting with human ACE2, which initiates the infection process. Furthermore, during this process, the S protein undergoes conformational changes induced by its entry into the endosomes of the host's cell. The S2 subunit acts as a fusion protein that helps in the union of the viral and host cell membranes [53, 54] . During the fusion process, the S2 protein appears in three consecutive conformational states: 1) prefusion (native state), 2) prehairpin (intermediate state), and 3) ensuing postfusion (hairpin state). Subsequently, surface proteases cleave S2. SARS-CoV-2 S protein has a furin site as an additional cleavage spot, which may be associated with the broader infectivity in comparison with SARS-CoV [55] . Understanding these dynamic conformation states that are associated with the mechanism of viral entry into the host cell membrane could lead to the development of effective therapeutics [32, 56] .

The S protein has been used as the antigen of all DNA vaccines currently being tested in clinical trials ( Table 1) . One of them, named AG0301-COVID19 (ClinicalTrials.gov number, NCT04463472), uses a two-immunization scheme, the first with a low dose Electroporation uses short electrical pulses at the vaccine application site, resulting in an increased cell membrane permeability; improved absorption of the antigen; and, consequently, a more effective immune response [58] . Moreover, electroporation was associated with an enhancement of immune response by recruiting inflammatory cells and APCs to the application site [59] .

Vaccine vectors have several advantages: low cost, noninvasive administration, and high safety levels [60] . The bacTRL-Spike vaccine uses live, recombinant already published, whereas phases 2 and 3 are either analyzing results or ongoing (ClinicalTrials.gov number, NCT04470427). This vaccine uses lipid nanoparticle (LNP)-encapsulated mRNA that encodes for a full-length, prefusion stabilized S protein of SARS-CoV-2 [68] [69] [70] .

Previous studies with similar formulations have demonstrated that the delivery of the mRNA vaccine has been optimized by using LNPs for intramuscular or intradermal administration [71, 72] . Data showed that mRNA-1273 induced both potent neutralizing antibody and CD8 T cell responses. In addition, it protected against SARS-CoV-2 infection in the lungs and nose of mice without evidence of immunopathology [73, 74] . Another mRNA vaccine, the BNT162 (BioNTech, Mainz, Germany) is in advanced clinical trials and has four variants, namely, a1, b1, b2, and c2. It is another LNP mRNA vaccine that recently made the results of the phase 1/2 trial public but not yet peer reviewed [76] . In this study, only the BNT162b1 variant was tested in a prime-boost J o u r n a l P r e -p r o o f Journal Pre-proof regimen within 21 days in three different doses [77] . Similar to mRNA-1273, the adverse events were dose-dependent and only mild to moderate, while the immune response showed a high level of neutralizing antibodies. Overall, these data suggest the potential to develop DNA and mRNA vaccines that are easier to design and can quickly proceed into clinical trials, which will be helpful for pandemic states such as the one caused by COVID-19 [77] .

Immunoinformatics is a branch of bioinformatics used to design vaccines against several infectious diseases [78] [79] [80] . This approach involves computational analysis of immunological data by predicting appropriate antigens, epitopes, carriers, and adjuvants for vaccine development. Therefore, immunoinformatics can reduce the time and cost of vaccines [81, 82] . Considering this, the design of novel multiepitope mRNA vaccines consisting of cytotoxic T lymphocyte, helper T lymphocyte, and linear B lymphocyte epitopes derived from SARS-CoV-2 S protein, as well as adjuvant highly immunogenic, have been analyzed [53, 81, [83] [84] [85] .

Furthermore, different DNA vaccine candidates expressing different forms of the SARS-CoV-2 S protein have been evaluated in 35 rhesus macaques. Vaccinated animals developed humoral and cellular immune responses, including neutralizing antibody titers that are comparable to those found in convalescent humans [86] . From a general perspective, although mRNA vaccines quickly advanced to clinical trials in humans, the majority of candidate DNA vaccines are currently in the preclinical stage.

J o u r n a l P r e -p r o o f Journal Pre-proof COVID-19 is an unusual global health threat wherein the vaccine is needed immediately. Because of the high risk of collapsing healthcare systems in several countries, governments had to implement lockdown measures, including no international travel and other public containment measures in attempting to reduce the virus morbidity and mortality worldwide [87] [88] [89] . Although effective, these actions led to vast economic devastation.

Until date, there is no effective drug to reduce the infection and pandemic burden [90, 91] . However, exceptional efforts have been made in attempting to develop an effective and safe vaccine at the earliest, which should be available to all countries affected by the pandemic at an affordable price [92, 93] . Previous advancements made since the SARS and MERS outbreaks have accelerated our understanding of the epidemiology, pathogenesis, and diagnosis of SARS-CoV-2, as well as the development of therapies to treat viral infection and possible vaccines [68] .

In this pandemic situation, it is crucial to ensure that rigorous and adequate clinical trials are performed to evaluate drugs with antiviral effects for avoiding the usage of ineffective and unsafe drugs [68] . Current clinical trials of candidate vaccines are undergoing phase 1 or parallel 1/2 studies to initiate phase 3 at the earliest and decrease the time required for the development of the new vaccine [74] .

Although advances in genetic sequencing and other technological developments have sped up the establishment of various vaccine platforms, several uncertainties still remain. Questions have arisen regarding the mutation rates of SARS-CoV-2, which could lead to immune evasion. Understanding mutations in the coding and non-coding regions, genetic diversity, pathogenicity, and host-pathogen interactions is essential.

Mutations in the S protein seem to induce conformational changes, which may alter antigenicity and, thus, may affect the vaccine design [32, 94, 95] . Moreover, previous J o u r n a l P r e -p r o o f Journal Pre-proof studies suggested that various mutations in the target proteins of the coronaviruses can be associated with drug resistance and changes in the protein structures of target proteins that may lead to vaccine inefficacy [32] .

It is crucial to highlight that the uncertainty over long-lasting protection against COVID-19 still remains. Patients with reinfection have been reported, and it is necessary to determine how long a protective immune response can be maintained in an individual [96, 97] . Considering the immunogenicity of the SARS-CoV-2 mRNA-1273 vaccine in older adults, it has been reported that after the second immunization, serum neutralizing activity was detected in all the participants, and binding and neutralizing antibody responses appeared to be similar to those described among vaccine recipients between the ages of 18 and 55 years and were above the median of a panel of control individuals who had donated convalescent serum [98] . Ideally, vaccination would induce long-lived immunity, but annual vaccination would be feasible based on experiences with the annual influenza vaccine [12] .

In the current pandemic, several specialists have suggested that immune responses against SARS-CoV-2 could lead to antibody-dependent enhancement (ADE) [99] .

Although this phenomenon has major importance for Flavivirus and some feline coronaviruses, SARS-CoV and SARS-CoV-2 have shown not to cause this effect in living animals or humans [100] . However, if ADE becomes crucial during the current pandemic, both DNA-and RNA-based platforms could quickly provide alternatives to circumvent such issues, as regions or motifs of the vaccine antigen responsible for causing ADE could be easily engineered or removed [101] .

The great advantage of the current advancements in nucleic acid-based technologies for vaccine development is the short time required from the design to clinical trials. Therefore, it may be soon possible to test together, in the same vaccine, different J o u r n a l P r e -p r o o f Journal Pre-proof variants of antigens that cover circulating mutations. This would represent a major step forward in vaccine development against rapidly emerging threats such as the current SARS-CoV-2 pandemic. Therefore, developing vaccines against COVID-19 require further studies on gene mutations and how to avoid vaccine failure because of them.

The authors have declared no conflict of interest. Therefore, macrophages are also activated to support cell-mediated immune responses (step 2b). However, CD4+ T helper cell activation is triggered through MHC class II from APC (step 3). In case the vaccine proteins are secreted, these targets are recognized by B cell receptors in naïve B cells, which also use MHC-II to get activated (step 4). In this immune pathway, activated B cells will produce different classes of antibodies (mainly IgG) to protect against the disease (step 5). Furthermore, immunization with DNA vaccine expresses proinflammatory cytokines and chemokines. DCs are responsible for producing IL-10, IL-12, and TNF-α that induce the cellular response by activating CD8+ T and IL-4 is involved in activating CD4+ T.

J o u r n a l P r e -p r o o f Journal Pre-proof

Vaccine development and therapeutic design for 2019-nCoV/SARS-CoV-2: Challenges and chances

Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of

Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) -an update on the status

WHO Director-General's opening remarks at the media briefing on COVID-19 -11

Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2? Frontiers in immunology

COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning. bioRxiv : the preprint server for biology

Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development

Toward effective COVID19 vaccines: Updates, perspectives and challenges (Review). International journal of molecular medicine

Transforming vaccine development

An update on the global vaccine development for coronavirus

Next-generation vaccine platforms for COVID-19

Emerging Concepts and Technologies

An effective DNA vaccine platform for Middle East respiratory syndrome coronavirus

New vaccine platform?

Developing Covid-19 Vaccines at Pandemic Speed. The New England journal of medicine

Vaccine development in the SARS-CoV-2 pandemic: a balancing act on accuracy and speed

Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert review of vaccines

Direct gene transfer into mouse muscle in vivo

DNA vaccines against leptospirosis: A literature review

A Review of DNA Vaccines Against Influenza

DNA vaccines for targeting bacterial infections. Expert review of vaccines

Parameters predicting COVID-19-induced myocardial injury and mortality

The trinity of COVID-19: immunity, inflammation and intervention

The future of human DNA vaccines

Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives

Machine learning using intrinsic genomic signatures for rapid classification of novel pathogens: COVID-19 case study

The broad-spectrum antiviral recommendations for drug discovery against COVID-19. Drug metabolism reviews

Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach

Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). The Journal of pathology

The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor-and angiotensin II receptor blocker-based cardiovascular therapies. Internal and emergency medicine

Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein

SARS vaccines: where are we? Expert review of vaccines

Induction of T-cell response by a DNA vaccine encoding a novel HLA-A*0201 severe acute respiratory syndrome coronavirus epitope

A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates

MERS-CoV vaccine candidates in development: The current

First clinical trial of a MERS coronavirus DNA vaccine. The Lancet Infectious diseases

Passive Immunization Toward Magic Bullets

Maternally-derived passive immunity to enterotropic mouse hepatitis virus

Retest positive for SARS-CoV-2 RNA of "recovered" patients with COVID-19: Persistence, sampling issues, or reinfection? Journal of medical virology

Will we see protection or reinfection in COVID-19?

COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation! Journal of clinical and experimental hepatology

A decade after SARS: strategies for controlling emerging coronaviruses

Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved Functional Regions of Viral Proteins

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

immunogenicity of a DNA vaccine candidate for COVID-19

Synthetic DNA vaccine strategies against persistent viral infections. Expert review of vaccines

Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1

DNA vaccine immunogenicity by in vivo electroporation

Oral immunization of mice using Bifidobacterium longum expressing VP1 protein from enterovirus 71

Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus

Oral administration of genetically modified Bifidobacterium displaying HCV-NS3

multi-epitope fusion protein could induce an HCV-NS3-specific systemic immune response in mice

Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine

Three decades of messenger RNA vaccine development

The promise of mRNA vaccines: a biotech and industrial perspective. npj Vaccines

mRNA vaccines -a new era in vaccinology

New Vaccine Technologies to Combat Outbreak Situations

Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines. Biomedical journal

Self-Amplifying Replicon RNA Delivery to Dendritic Cells by Cationic Lipids

Nonviral delivery of self-amplifying RNA vaccines

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness. bioRxiv : the preprint server for biology

Vaccines for COVID-19: The current state of play. Paediatric respiratory reviews

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report. The New England journal of medicine

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim

Vaccination strategies to combat novel corona virus SARS-CoV-2. Life sciences

An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transgenic mice

Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach

Computational tools for epitope vaccine design and evaluation. Current opinion in virology

A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerging microbes & infections

Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

COVID-19 human challenge studies: ethical issues. The Lancet Infectious diseases

Counting the cost of COVID-19. International journal of information technology : an official journal of Bharati Vidyapeeth's Institute of Computer Applications and Management

Historical evidence for economic effects of COVID-19. The European journal of health economics : HEPAC : health economics in prevention and care

Covid-19: current knowledge, disease potential, prevention and clinical advances

COVID-19 created chaos across the globe: Three novel quarantine epidemic models

Covid-19: Trump sought to buy vaccine developer exclusively for US, say German officials

Emerging viruses and current strategies for vaccine intervention

study on the resistance of severe acute respiratory syndrome-associated coronavirus

Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance

COVID-19 reinfection in an healthcare worker

reinfection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. The New England journal of medicine

Molecular Mechanism for

Antibody-Dependent Enhancement of Coronavirus Entry

The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibodydependent enhancement. bioRxiv : the preprint server for biology

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies